Parkinson Disease
📧 Sign up to get email alerts when something new happens for Parkinson Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-01-20Clinical Trial Update: Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure [Phase 3]
Phase 3 trial of TD-9855 for symptomatic neurogenic orthostatic hypotension was terminated; results were posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-01-10Clinical Trial Update: Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm [Phase 1, Phase 2]
A completed Phase 1/2 trial examining transdermal flumazenil to modulate GABA-A receptors in Parkinson disease; results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Varenicline for Gait and Balance Impairment in Parkinson Disease [Phase 2]
Phase 2 trial update of varenicline for gait and balance impairment in Parkinson disease has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) [Phase 3]
Phase 3 trial update comparing an investigational drug to an approved treatment for Parkinson's disease with motor OFF episodes; study statu…
-
CLINICAL_TRIALS trial_result · 2022-12-13Clinical Trial Update: Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease [Phase 4]
A Phase 4 clinical trial evaluated memantine (Namenda) for non-motor symptoms in Parkinson's disease; study completed with results posted in…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-02Clinical Trial Update: Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease [Phase 3]
Phase 3 open-label continuation study of levodopa-carbidopa intestinal gel in advanced Parkinson's disease has completed with results posted…
-
FDA approval · 2022-11-30FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approved a supplemental application for DATSCAN (IOFLUPANE I-123) by Medi-Physics Inc. dba GE Healthcare, indicating an update to the la…
-
FDA approval · 2022-11-28FDA Approved: CARBIDOPA AND LEVODOPA — Original Application (Aurobindo Pharma Limited)
FDA approved a generic carbidopa-levodopa product under an Original Application by Aurobindo Pharma Limited.
-
FDA approval · 2022-11-21FDA Approved: CARBIDOPA AND LEVODOPA — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for Amneal Pharmaceuticals NY LLC for CARBIDOPA AND LEVODOPA (carbidopa-levodopa).
-
CLINICAL_TRIALS trial_result · 2022-11-18Clinical Trial Update: Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease [Phase 3]
Phase 3 trial comparing continuous subcutaneous infusion of ABBV-951 with oral carbidopa/levodopa in adults with advanced Parkinson's diseas…
-
CLINICAL_TRIALS trial_result · 2022-11-10Clinical Trial Update: Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease [NA]
Completed clinical trial evaluating cerebellar transcranial direct current stimulation in Parkinson's disease; results posted in 2022.
-
CLINICAL_TRIALS research · 2022-11-10Clinical Trial Update: Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology [NA]
A completed clinical trial evaluating directional deep brain stimulation technology for dystonia in Parkinson's disease patients; results po…
-
FDA approval · 2022-11-08FDA Approved: BROMOCRIPTINE MESYLATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for bromocriptine mesylate from Sandoz Inc, approving a modification to an existing generic product'…
-
FDA approval · 2022-11-01FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)
FDA approved a supplemental application for DATSCAN (ioflupane I-123) by Medi-Physics Inc. dba GE Healthcare.
-
CLINICAL_TRIALS trial_result · 2022-10-31Clinical Trial Update: Vestibular Stimulation in Parkinson's Disease [NA]
Clinical trial on vestibular stimulation for Parkinson's disease has completed with results posted in 2022.
-
FDA approval · 2022-10-28FDA Approved: ROPINIROLE — Supplemental Application (Marlex Pharmaceuticals Inc)
FDA approved a supplemental application for a generic ropinirole product manufactured by Marlex Pharmaceuticals Inc.
-
FDA approval · 2022-10-27FDA Approved: ROPINIROLE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application for ropinirole submitted by Glenmark Pharmaceuticals Inc., USA, updating the approved product.
-
FDA approval · 2022-10-27FDA Approved: ROPINIROLE — Supplemental Application (Bionpharma Inc.)
FDA approved a supplemental application for ropinirole submitted by Bionpharma Inc., under an already approved ANDA.
-
CLINICAL_TRIALS trial_result · 2022-10-27Clinical Trial Update: NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) [Phase 2]
Phase 2 clinical trial update for NYX-458 in subjects with mild cognitive impairment or mild dementia due to Parkinson's disease or Lewy bod…
-
CLINICAL_TRIALS trial_result · 2022-10-10Clinical Trial Update: Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment [Phase 2]
Phase 2 clinical trial assessing AKST4290 for Parkinson's disease patients on stable dopaminergic therapy has completed and posted results i…
-
CLINICAL_TRIALS trial_result · 2022-09-28Clinical Trial Update: Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD) [Phase 2]
Phase 2 trial evaluating Xyrem for excessive daytime sleepiness and sleep disturbance in Parkinson's disease has completed with results post…
-
CLINICAL_TRIALS trial_result · 2022-09-26Clinical Trial Update: TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) [Phase 2]
Phase 2 clinical trial update for TD-9855 in neurogenic orthostatic hypotension (nOH) completed with results posted.
-
FDA approval · 2022-09-21FDA Approved: CARBIDOPA-LEVODOPA — Original Application (Advagen Pharma Ltd.,)
The FDA approved Advagen Pharma's original application for a generic carbidopa-levodopa product.
-
CLINICAL_TRIALS trial_result · 2022-09-13Clinical Trial Update: Exenatide Treatment in Parkinson's Disease [Phase 2]
Phase 2 clinical trial investigating exenatide treatment for Parkinson's disease is ongoing, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2022-09-06Clinical Trial Update: Brain Perfusion & Oxygenation in Parkinson's Disease With NOH [Phase 4]
Phase 4 trial update on brain perfusion and oxygenation in Parkinson's disease with neurogenic orthostatic hypotension has completed.